

Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, April 28, 2022  
Alfresa Holdings Corporation

**Notice Regarding Revision to Consolidated Performance Forecast**  
**[Prepared on the Basis of Japan's Generally Accepted Accounting Principles (GAAP)]**

Due to the current business environment, the Company revised its consolidated performance forecast for the full year ending March 31, 2022 (April 1, 2021 - March 31, 2022), which was previously announced on February 7, 2022.

**1. Revision of Consolidated Performance Forecast for the Full Year Ending March 31, 2022**

	Net sales	Operating income	Ordinary profit	Profit attributable to owners of the parent	Basic earnings per share
	¥ Million	¥ Million	¥ Million	¥ Million	Yen
Previous projection (A)	2,578,000	21,900	25,500	29,000	140.71
Revised projection (B)	2,585,000	29,000	32,400	32,100	153.30
Change (B-A)	7,000	7,100	6,900	3,100	-
Percentage change (%)	0.3	32.4	27.1	10.7	-
(Ref.) Results for the full year ended March 31, 2021	2,610,427	27,929	31,918	24,501	115.75

Note: The Company has changed the accounting policies due to the application of the "Accounting Standard for Revenue Recognition," etc. and the presentation method of information fees, etc. The results for the full year ended March 31, 2021 are retroactively revised due to reflecting changes in the presentation method of information fees, etc.

**2. Reason for Revision of Consolidated Performance Forecast**

Regarding consolidated financial performance in the fiscal year ending March 31, 2022, net sales, operating income, ordinary profit, and profit attributable to owners of the parent are expected to exceed previous forecasts due to higher-than-expected market growth, growth in products related to the COVID-19 pandemic and medical products, and efforts to contain selling, general and administrative expenses.

Considering the above factors, the Company has decided to revise its full-year consolidated performance forecast for the fiscal year ending March 31, 2022, which was previously announced on February 7, 2022.

**\*Disclaimer regarding the Appropriate Use of Performance Forecasts and Other Notes**

The forward-looking statements such as performance forecasts contained herein are forecasts based on the Company's current possessed information and certain assumptions deemed to be reasonable. Actual performance may differ substantially from these forecasts due to various factors.

**About Alfresa Group**

The Alfresa Group is a leader in Japanese healthcare industry, which is dedicated to make its corporate philosophy "we create and deliver a fresh life for all" come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported its consolidated revenue of ¥2.6 trillion (US\$24 billion) for the fiscal year ended March 31, 2021. For more information, please see: <https://www.alfresa.com/eng/>